14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs CORT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin).
Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs CORT. Trailing 12-month operating profitability (SYRE 0.0% vs CORT 11.5%) and valuation multiples (SYRE N/M vs CORT 14.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $8.1B market capitalization and 11.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs CORT Key Questions & Quantitative Answers
As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CORT leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CORT at +64.0% YoY revenue growth and +531.3% YoY earnings growth on $964M TTM revenue (98.5% gross margin, 11.5% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $964M for CORT. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CORT.
CORT screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CORT trades at 14.6x Forward P/E, 55.4x Trailing P/E, 0.81x PEG, and 8.3x EV/Revenue (20.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus CORT (22.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, CORT carries 53.1% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.63β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.